Detection of proteins from circulating neoplastic cells
US8012480B2 · kind B2 · utility
6Cited by
0References
12Claims
0Family size
Assignee
Inventor
Key dates
| Filing date | Apr 18, 2007 |
| Grant date | Sep 6, 2011 |
| Priority date | — |
| Expiry date | Oct 6, 2027 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/00
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The protein EGFR, ERCC1, RRM1, thymidylate synthase, or beta-tubulin from cancer cells is detected in a blood sample by enriching the cancer cells from the blood sample followed by performing on the enriched cancer cells an immunoassay capable of detecting the proteins mentioned above. Cancer patients overexpressing EGFR are treated with an anti-EGFR agent, for example cetuximab, panitumumab, erlotinib or gefitinib.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.